<DOC>
	<DOCNO>NCT01917331</DOCNO>
	<brief_summary>Randomized , double-blind , multicenter , multinational , parallel-group , Phase III study demonstrate superiority triple fix combination Beclometasone+Formoterol+Glycopyrrolate ( BDP/FF/GB ) administer via pMDI equivalent dose Foster® COPD ( Chronic Obstructive Pulmonary Disease ) patient 52 week treatment</brief_summary>
	<brief_title>Efficacy Fixed Combination Beclometasone + Formoterol + Glycopyrrolate Versus Foster® COPD</brief_title>
	<detailed_description>This 52-week randomise 2 parallel group study aim evaluate superiority fix triple therapy ICS/LABA/LAMA compare ICS/LABA severe severe COPD patient . Patients ' eligibility check screening visit include review medical history , spirometry assessment , routine lab , physical examination , 12-lead ECG , vital sign measurement . This visit follow 2-week open-label run-in period Foster® ( BDP/FF 400/24 µg total daily dose ) . Eligible patient randomise either fixed triple therapy BDP/FF/GB BDP/FF . During 52-week treatment period , complete patient 5 subsequent visit post randomisation schedule respectively 4 ( Visit 3 ) , 12 ( Visit 4 ) , 26 ( Visit 5 ) , 40 ( Visit 6 ) 52 ( Visit 7 ) week treatment . During , pre-dose post-dose spirometry , 12-lead ECG , vital sign , dyspnea assessment perform . Rescue medication use , compliance treatment EXACT-PRO questionnaire record daily ( via electronic diary ) run-in randomise treatment period .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Male female adult age ≥ 40 year diagnosis COPD Current smokers exsmokers A postbronchodilator FEV1 &lt; 50 % predict normal value post bronchodilator FEV1/FVC &lt; 0.7 At least one exacerbation 12 month precede screen visit Pregnant lactate woman Diagnosis asthma history allergic rhinitis atopy Patients treat noncardioselective βblockers month precede screen visit Patients treat exacerbation 4 week prior screen visit Patients treat longacting antihistamine unless take stable regimen least 2 month prior screen maintain constant study take PRN Patients require long term ( least 12 hour daily ) oxygen therapy chronic hypoxemia Known respiratory disorder COPD Patients clinically significant cardiovascular condition</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>spirometry</keyword>
	<keyword>severe COPD</keyword>
	<keyword>lung disease</keyword>
	<keyword>fix combination</keyword>
</DOC>